Prognostic relevonce of the plasminogen activation system in tissue of patients with gastric cancer

Ganesh, Shanthi; Sier, C.F.M.; Heerding, M.M.; Griffioen, G.; Lamers, C. B. H. W.; Verspaget, Hein W.

doi:10.1016/0300-2977(95)97043-o

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gastric cancer is the most common gastrointestinal cancer with high mortality worldwide. The vast majority of gastric cancer cases detected are in the advanced stage [1]. The poor prognosis and treatment of gastric cancer are highly relative to metastasis [2].…”

Section: Introductionmentioning

confidence: 99%

Sulforaphane Suppresses the Nicotine-Induced Expression of the Matrix Metalloproteinase-9 via Inhibiting ROS-Mediated AP-1 and NF-κB Signaling in Human Gastric Cancer Cells

Khoi

Yin

et al. 2022

IJMS

View full text Add to dashboard Cite

Sulforaphane, a natural phytochemical compound found in various cruciferous vegetables, has been discovered to present anti-cancer properties. Matrix metalloproteinase-9 (MMP-9) plays a crucial role in gastric cancer metastasis. However, the role of sulforaphane in MMP-9 expression in gastric cancer is not yet defined. Nicotine, a psychoactive alkaloid found in tobacco, is associated with the development of gastric cancer. Here, we found that sulforaphane suppresses the nicotine-mediated induction of MMP-9 in human gastric cancer cells. We discovered that reactive oxygen species (ROS) and MAPKs (p38 MAPK, Erk1/2) are involved in nicotine-induced MMP-9 expression. AP-1 and NF-κB are the critical transcription factors in MMP-9 expression. ROS/MAPK (p38 MAPK, Erk1/2) and ROS functioned as upstream signaling of AP-1 and NF-κB, respectively. Sulforaphane suppresses the nicotine-induced MMP-9 by inhibiting ROS-mediated MAPK (p38 MAPK, Erk1/2)/AP-1 and ROS-mediated NF-κB signaling axes, which in turn inhibit cell invasion in human gastric cancer AGS cells. Therefore, the current study provides valuable evidence for developing sulforaphane as a new anti-invasion strategy for human gastric cancer therapy.

show abstract

Section: Introductionmentioning

confidence: 99%